Public

US Securities Class Action

Talis Biomedical reached a settlement with $TLIS investors to resolve claims that it misled them about delays in approval and launch of the Talis One COVID-19 test. 

Talis Biomedical Corp

All persons or entities who purchased or otherwise acquired Talis Biomedical Corporation common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with Talis’s February 11, 2021 initial public offering, between February 11, 2021 and August 11, 2021, inclusive, and were damaged thereby.

Do I have to sell securities to be eligible?

No, if you have purchased securities within the class period, you are eligible to participate.

You can participate in the settlement and retain (or sell) your securities.

The entire process usually takes 4 to 9 months after the claim deadline. But the exact timing depends on the court and settlement administration.

The final payout amount depends on your specific trades and the number of investors participating in the settlement.

If 100% of investors file their claims - the average payout will be $2.05 per share. Although typically only 25% of investors file claims, in this case, the average recovery will be $8.20per share.

If you're eligible, you can file your claim directly from this case page by clicking the "Collect Payout" button.

More than 100 companies are currently paying out settlements. Connect your brokerage account to automatically check which ones you may have missed — or file manually for this case.

11thestate is an investor recovery company, we help investors to track and collect securities class action settlements. We will:

Audit the claim and make sure you get the maximum possible payout.

File a claim with the settlement administration.

Correspond with the settlement administration to resolve emerging issues.

Deliver payout directly to your brokerage account.

There is no upfront cost, but we will deduct 20% of the recovered amount as a commission for our services.

Talis Biomedical (TLIS) Investor Settlement

Frequently Asked Questions

Trusted by industry leaders